Log In
BCIQ
Print this Print this
 

ACP-01

  Manage Alerts
Collapse Summary General Information
Company Hemostemix Inc.
DescriptionAngiogenic autologous cell therapy
Molecular Target
Mechanism of Action 
Therapeutic ModalityCell therapy
Latest Stage of DevelopmentPhase II
Standard IndicationIschemia / reperfusion injury
Indication DetailsTreat critical limb ischemia (CLI)
Regulatory Designation
PartnerHemostemix Asia Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$0.1M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/23/2015

Undisclosed

0

0

06/07/2015

$0.1M

0

0

Get a free BioCentury trial today